1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP)-Formulated, Immune-Stimulatory Vascular Endothelial Growth Factor A Small Interfering RNA (siRNA) Increases Antitumoral Efficacy in Murine Orthotopic Hepatocellular Carcinoma with Liver Fibrosis
- 3 Downloads
Most experimental therapy studies are performed in mice that bear subcutaneous or orthotopic hepatoma but are otherwise healthy and nonfibrotic. The majority of hepatocellular carcinoma (HCC), however, develops in patients suffering from preexisting liver fibrosis. We investigated the efficacy of a standard experimental therapeutic approach to interrupt the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) cascade via VEGF-A silencing, with or without 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP; cationic lipid) formulation, in HCC mice with preexisting liver fibrosis. The data show that intraperitoneal treatment with naked VEGF-A small interfering RNA (siRNA; 200 µg/kg) was inefficient to treat HCC implanted into fibrotic livers. VEGF-A siRNA containing an immunostimulatory motif in combination with DOTAP formulation significantly reduced hepatic VEGF-A expression and additionally activated the innate and adapted immune system as shown by an increased intrahepatic interferon type 1 response (68-fold increased β-interferon expression). DOTAP-formulated VEGF-A siRNA markedly improved VEGF-A siRNA uptake and enhanced the antitumor response. This study shows for the first time the therapeutic feasibility of using synergistic effects (gene silencing and activation of the immune system) united in one siRNA sequence to reduce HCC growth and metastasis in mice with preexisting liver fibrosis. We expect that these results will help to direct and improve future experimental gene-silencing approaches and establish more efficient antitumoral therapies against HCC.
In 1978, the World Health Organization defined cirrhosis as “a diffuse process characterized by fibrosis and the conversion of normal liver architecture into structurally abnormal nodules.” One of the most common causes of hepatic fibrosis is chronic alcohol abuse; other factors also have the potential to trigger hepatic fibrogenesis (1).
Liver fibrosis is of utmost relevance for hepatocellular carcinogenesis (HCC). Malignant hepatocellular transformation is characterized by a shortened half-life and increased proliferation and regeneration of hepatocytes secondary to ongoing inflammation (2). This leads to accumulation of genomic mutations and instability, alterations that sometimes accumulate in a neoplastic phenotype (3). For that reason, HCC is strongly associated with chronic liver diseases, including chronic hepatitis and cirrhosis. In fact most cases of HCC, approximately 80%, occur in combination with underlying cirrhosis (4,5); <10% are observed in noncirrhotic livers, rarely without hepatitis (6). Notably, once cirrhosis is established there is no proven effective HCC prevention, yet (7). Recently, we showed that hepatic fibrosis relevantly accelerates orthotopic HCC tumor growth and metastasis in fibrotic C3H/He mice (8). Kuriyama et al. (9) reported that fibrosis seemed to affect metastasis. However, there is still the need for a robust murine liver fibrosis model to investigate antitumor efficacy.
Angiogenesis plays a major role in a wide range of biological processes, such as wound healing, organ regeneration, and the female reproduction cycle. Under normal conditions, angiogenesis otherwise does not occur in an adult organism but is needed for further tumor growth. Vascular endothelial growth factor (VEGF) is a major player in tumor angiogenesis, and the VEGF/VEGF receptor (VEGFR) pathway is a major focus of interest in basic cancer research (10). Several studies have used gene silencing targeted against VEGF-A mRNA in distinct tumor models (11, 12, 13, 14).
There are no data on functional VEGF-A knockdown in HCC with preexisting hepatic fibrosis. Here, we applied 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated small interfering RNA (siRNA) targeted against VEGF-A to control HCC in mice with preexisting hepatic fibrosis.
Materials and Methods
Animals and Cell Lines
C3H/He female mice (age matched) were obtained from Charles River (Sulzfeld, Germany) and housed under SPF conditions in the central animal facility of the University Hospital Bonn. Animal procedures were performed in accordance with approved protocols of the responsible local governmental administration and followed recommendations for proper care and use of laboratory animals.
Hepa129 cells (hepatoma 129 originating from C3H/He mice, obtained from NCI-Frederick Cancer Research and Development Center [DCT Tumor Repository; Frederick, MD, USA]) were maintained in RPMI 1640 (Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS) (Invitrogen), 200 mM glutamine, and penicillin/streptomycin.
Administration of Thioacetamide and EtOH
Before tumor cell implantation, induction of fibrosis was studied in female C3H/He mice using i.p. injections of thioacetamide (TAA) (Sigma-Aldrich, Taufkirchen, Germany; 0.15 mg/g body weight) three times per wk for up to 24 wks in combination with alcohol feeding in sweetened drinking water (10% vol/vol) according to a published protocol (8,15,16).
Tumor Cell Implantation
To minimize postoperational mortality, TAA administration was paused for up to 7 d after tumor cell implantation. At d 7 and 9, all mice received TAA i.p. again. EtOH feeding via drinking water was maintained.
siRNA used in this study were purchased from Dharmacon/Perbio Science Deutschland (Bonn, Germany) and received as desalted, pre-annealed duplexes in standard purified batches. One siRNA batch was fluorescein labeled for evaluation of the transfection efficiency. The sense strands sequences were as follows: VEGF, 5′-AUGUGAAUGCAGACCAAAG AA-dTdT; CONTRL, 5′-GAUAGCAAUGACGAAU GCGUAdTdT, according to a publication by Filleur et al. (18).
For van Gieson staining, 4% formaldehyde-fixed liver samples were paraffin embedded, and 5-µm sections were stained according to a standard protocol. Fibrosis was assessed according to the fibrosis scoring system proposed by Ishak et al. (22) (no fibrosis F0, cirrhosis F6).
To determine cell proliferation, cryopreserved liver sample sections were immunostained with rabbit antimouse Ki-67 (1:25; Dako, Hamburg, Germany) and incubated with a biotinylated antirabbit swine IgG secondary antibody (Dako) and streptavidine peroxidase. Enzymatic activity was developed using 3-amino-9-ethylcarbazole (AEC; Dako) as substrate, and sections were counterstained with Mayer hematoxylin. For Ki-67 immunofluorescence staining, cryopreserved liver sample sections from FL-siRNA-treated (±DOTAP) fibrotic HCC implanted mice were immunostained with rat antimouse Ki-67 (1:25; Dako) and incubated with Alexa Fluor 546 goat antirat secondary antibody (Molecular Probes, Leiden, The Nederlands).
RNA, cDNA Preparation, and Semiquantitative Real-Time PCR (Liquid Chromatography)
Specific primer oligonucleotides and oligonucleotide probes for PCR.
AAA TCA GTT ATG GTT CCT TTG GTC
TCC TCT CC
GCT CTA GAA TTA CCA CAG TTA TCC AA
GCA GCT TGA GTT AAA CGA ACG
CCA GGC TG
GGT TCC CGA AAC CCT GAG
ACA GCC TTT GCC TCA TCT TG
CAG CCT CG
TGG AGG ATC CAC CTG TTG TT
CTG TAG CCC ACG TCG TAG C
TGG AGG AG
TTG AGA TCC ATG CCG TTG
CAT GAT GGC TCC CTT TTT CA
CAG CAG GA
GTC ACC TGG TTG CTG CAA TA
All data are given as arithmetic means with SD. Differences between values of independent experimental groups were analyzed for statistical significance by Mann-Whitney U test. An error level P < 0.05 indicates significance.
Histological and Immunohistological Assessment of Fibrosis
To verify liver fibrosis induction, van Gieson staining was performed 11 d after tumor cell implantation in paraffin sections from fibrotic mice treated for 24 wks with TAA i.p. and EtOH (Figure 2A). Similar to our previous publication (15), livers of TAA- and EtOH-treated mice showed fibrotic septa with predominant porto-porto bridging (Figure 2B and b). Additionally, hepatic regeneration nodules could be detected in several mice. When applying the Ishak scoring system (22), fibrosis was graded F4/5 (maximum F6).
Influence on Hepa129 Tumor Growth after Treatment with VEGF-A siRNA
Syngenic Hepa129 tumor cell implantation resulted in numerous HCC satellites in these fibrotic mice. In untreated mice, practically the complete left liver lobe was infiltrated by innumerable HCC satellites. No primary tumor nodule was distinguishable in these severely tumor-infiltrated livers. Eleven d after tumor cell implantation, HCC satellites were counted and four subgroups were selected depending on the satellite count (Figure 1A): >50 (Figure 1C), <50 and >30 (Figure 1D), <30 (Figure 1E), and no visible surface lesions.
In untreated control mice, 75% of the mice had >50 satellites and only 25% had <50 and >30 surface satellites. In the siRNA control group, some antitumor effects of scrambled control siRNA were observed: 25% of these mice had <50 and >30, 12.5% <30, and 6.25% no surface satellites at all. The distribution pattern between control siRNA and naked VEGF-A siRNA differed only slightly: 50% of the naked VEGF-A siRNA treated mice did not respond, about 22% had <50 and >30 surface satellites, 22% had <30, and 5.7% had no observable surface satellites.
In contrast to the results of treatment with naked VEGF-A siRNA, the DOTAP VEGF-A siRNA complex increased the antitumoral treatment efficacy in orthotopic hepatomas developing in liver fibrosis. The percentage of mice with <30 surface satellites increased by almost fourfold, from average 22% in the naked VEGF-A siRNA group to 82% in the corresponding DOTAP-formulated VEGF-A siRNA treatment group. Only 18% of mice treated with DOTAP VEGF-A siRNA had <50 and >30 surface satellites, and none had >50 surface satellites.
In line with previous results that DOTAP alone did not affect or activate the innate or adaptive immune system, the tumor burden of mice that had solely been injected with DOTAP fully resembled that of the control group. These data stem from two independent experiments; the detailed group sizes are given in Figure 1B.
Ki-67 Staining for Determination of Intratumoral Proliferating Cells 11 Days after siRNA Treatment Initiation
DOTAP FL-VEGF siRNA Detection
DOTAP VEGF-A siRNA Effect on Hepatic VEGF-A Expression
According to the uptake results, semiquantitative PCR results carried out against hepatic VEGF-A confirmed that the DOTAP VEGF-A siRNA formulation decreased VEGF-A transcription by a factor of 2.6 (62%) in peritumoral hepatic tissue compared with animals that did not receive any siRNA treatment (Figure 4A). Compared with mice treated with scrambled control siRNA, DOTAP VEGF-A siRNA significantly reduced hepatic VEGF-A by a factor of 1.7 (41%). When naked VEGF-A siRNA and DOTAP VEGF-A siRNA treatments were compared, intrahepatic VEGF-A silencing was considerably improved by a factor of 3 in favor of DOTAP siRNA VEGF-A. Again, no significant differences were measurable between the cohort treated with DOTAP alone and untreated controls.
DOTAP VEGF-A siRNA Effect on Intratumoral VEGF-A and HIF-1α Expression
Increased intratumoral VEGF-A expression was paralleled by raised intratumoral HIF-1α transcription (7.4-fold) in DOTAP VEGF siRNA-treated mice compared with untreated mice (Figure 5B). Naked VEGF-A siRNA also slightly augmented (2.7-fold) HIF-1α expression. Again, treatment with DOTAP alone did not affect intratumoral HIF-1α levels compared with untreated controls.
DOTAP VEGF-A siRNA Effect on Hepatic IFN-β Expression
DOTAP VEGF-A siRNA Effect on Hepatic Tumor Necrosis Factor-α Expression
DOTAP VEGF-A siRNA did not elevate tumor necrosis factor (TNF)-α expression but rather decreased it significantly, by 66% compared with naked VEGF-A siRNA treatment (Figure 6C). Interestingly, treatment with DOTAP alone resulted in TNF-α reduction by 92% compared with naked VEGF-A siRNA. In fact TNF-α stimulates a Th-1—mediated immune response and might therefore add, if elevated, to antitumoral effect of a DOTAP-complexed VEGF-A siRNA treatment. Because TNF-α upregulation was monitored in neither DOTAP- nor DOTAP siRNA-injected mice, stimulation of the Th-1-mediated immune response by TNF-α can be ruled out, as suggested by others (26).
Because HCC predominantly develops in damaged fibrotic liver tissue, it is desirable to combine hepatoma growth and chronic liver damage to imitate most closely the disease course of HCC in humans. This study was designed to elucidate the antitumor efficacy of an anti-VEGF-A HCC treatment in liver fibrosis. For this purpose, liver fibrosis was induced by a combination of TAA i.p. and EtOH. Once liver fibrosis was established, hepatomas were induced by tumor cell implantation. Subsequently, a functional VEGF-A knockdown applying different formulations of VEGF-A siRNA was used to interrupt the VEGF/VEGFR cascade in this model. Tumor burden and protein expression of related genes, namely VEGF-A and HIF-1α, were quantified. In this setting, the antitumor response could partly be attributed to immune-stimulating features of the siRNA sequence and partly to gene silencing of the VEGF-A target gene.
Several studies have been carried out to target the VEGF/VEGF receptor pathway via siRNA to treat tumors of different origin, like retinoblastoma, prostate carcinoma, colon adenocarcinoma, colon cancer, and glioblastoma in vitro and in vivo (12,13,27,28). Considering the role of VEGF in HCC, anti-VEGF therapies are of particular interest for this tumor entity. Usually, experimental antitumor strategies are tested in subcutaneous, but rarely in orthotopic, hepatoma models (29,30). Previously, the Hepa129 hepatoma cell line has been demonstrated to be suitable for orthotopic tumor growth and also for therapeutic intervention studies (29,31). Furthermore, our previous data demonstrated that liver fibrosis had a strong impact on orthotopic HCC growth. It appeared that preexisting fibrosis modulated Hepa129 tumor growth in such a way that tumor growth was accelerated by forming innumerous tumor satellites (8,16).
In this study, liver damage by TAA i.p. and EtOH administration resulted in F4/5 fibrosis as demonstrated by van Gieson collagen staining. Consonant with our former findings, orthotopic HCC growth severely infiltrated liver tissue in the case of preexisting fibrosis. In spite of VEGF upregulation in this model, treatment with naked VEGF-A siRNA did not relevantly inhibit tumor load. This finding was somewhat unexpected, because previous studies including our own using the same naked VEGF-A siRNA sequence achieved significant antitumoral effects in a prostate cancer s.c. xenograft model and also in Hep129 hepatomas in nonfibrotic mice (19,32). In the former models, tumors generally developed as single nodules that were successfully treated with the naked VEGF-A siRNA preparation. In contrast to those works, tumor growth was diffuse and infiltrative in the recent fibrotic HCC model. Thus, loss of antitumor efficacy may be attributed to irrelevance of VEGF-A in this model or to decreased siRNA uptake efficiency in vivo in liver fibrosis. Roberts et al. (33) blocked VEGFR3 with a neutralizing antibody, resulting in decreased metastasis in vivo. Here, we intended to overcome antitumor inefficacy of naked VEGF-A siRNA by DOTAP siRNA formulation. Indeed, labeled naked siRNA uptake was strongly improved when formulated with DOTAP, whereas intrahepatic and intratumoral fluorescence signals were rarely detectable in mice injected with naked siRNA. Enhanced uptake was well reflected in decreased hepatic expression of the target gene VEGF-A. It has been shown by others that naked siRNA modifications such as PEG formulation increase VEGF-A siRNA stability and protect against enzymatic degradation (11). Furthermore Liu et al. (34) reported that injection of lipoplexes through the portal vein after partial hepatectomy induced higher reporter gene expression (luciferase) in the liver than naked DNA injection. This earlier study already showed that the DOTAP formulation of DNA boosted its uptake and enhanced transfection efficiency.
Judge et al. (23) reported that DOTAP and poly U-rich siRNA complexes activate the innate and adapted immune system via IFN type 1 upregulation. The VEGF-A siRNA sequence employed in our study also contains a poly U-rich motif, which may trigger activation of the innate and adapted immune system via IFN type 1 upregulation as suggested. So far, three different immunestimulatory siRNA motifs have been described; none of these were capable of inducing an IFN type 1 response without DOTAP (23,24). A current review suggested that the merging of gene-silencing and immune-stimulation siRNA in one siRNA molecule may provide “two edges of one sword for effective treatment of cancer” (25). Consonant with the former finding, naked VEGF-A siRNA containing an immune-stimulatory motif did not induce IFN type 1 increase, confirming published in vitro and in vivo data (24,35,36). In contrast, hepatic IFN type 1 levels increased 68-fold in DOTAP VEGF-A siRNA-treated mice. IFNs might attribute to antitumoral efficacy in this setting by modulation of proliferation, differentiation, and the immune system (37). It has been reported that the systemic administration or gene delivery of IFNs exerted a therapeutic effect in some experimental models (38, 39, 40). Interestingly, it has been shown that highdose and long-term therapy with IFNs inhibited experimental HCC development and that IFN-β prevented recurrence of HCC in humans with chronic hepatitis C virus infection (41, 42, 43). Considering IFN expression levels in our study, IFNs (IFN type I) might add up to overall antitumor efficacy by anti-angiogenic or antiproliferative effects in this HCC model.
TNF-α is a well-known pro-inflammatory cytokine related to the Th-1 innate immune response. Together with IFN-β, TNF-α might be affected by siRNA and carry additional antitumor effects. However, Khazanov et al. (26) demonstrated that DNA-based lipoplexes (DOTAP) resulted in low levels of TNF-α, along with others. They concluded that the observed antitumoral effect cannot be ascribed to Th-1 inflammation, but rather to a direct cytotoxic effect on the tumor cells. Our DOTAP-only results ruled out the latter hypothesis, because we did not observe any tumor load differences between the untreated and the DOTAP-only cohorts.
In earlier studies, we demonstrated that tumor-bearing nonfibrotic mice that were systemically treated with AdsFlk-1 showed a strong increase of circulating VEGF, whereas VEGF remained at background levels in controls. Furthermore, VEGF determination in liver tissue homogenates showed a 16.5-fold increase in AdsFlk-1-treated animals compared with AdLacZ controls (30). Additionally, Bocci et al. (48) suggested that detection of elevated VEGF values even presents a suitable biochemical surrogate marker for antitumor response to a successful antitumoral therapy, although we did not confirm this finding in AdsFlk-1-treated colorectal cancer (30).
In summary, naked VEGF-A siRNA was ineffective to control tumor load in liver fibrosis in this study, whereas DOTAP VEGF-A siRNA reestablished antitumor efficacy partially because of improving intratumoral siRNA uptake. Our data imply that immune-stimulatory siRNA motifs can work in concert with target-specific gene silencing. Thus, the purposeful design of a DOTAP-formulated siRNA sequence targeting a specific tumor relevant gene and simultaneously inducing an immune-stimulatory effect can be helpful to treat experimental HCC.
This work was partly supported by a Deutsche Krebshilfe and a DFG grant to V.S. No conflicts of interest exist.
We thank Prof. P.A. Knolle, head of the Institute of Molecular Medicine and Experimental Immunology (IMMEI, Bonn, Germany) for continuous support of the project. Additionally we thank our practicum-student Bettina Schroll for her assistance during the tumor implantation surgery.
- 4.Johnson RC. (1997) Hepatocellular carcinoma. Hepatogastroenterologgy 44:307–12.Google Scholar